ZAXOL-300 (Paclitaxel Injection 300mg/50ml)

Rated 0 out of 5
(0 customer reviews)

Description: Zaxol-300 contains Paclitaxel, a chemotherapeutic agent used in cancer treatment. It is primarily administered through intravenous infusion. This medication is available in a 300 mg/50 ml strength and must be diluted before administration. It is used under the supervision of a qualified oncologist to treat various types of cancers, including breast, ovarian, and lung cancer.

48,000.00

Hurry Up! Sales Ends In:

In stock

Guaranteed Safe Checkout

ZAXOL-300 (Paclitaxel 300mg I.P) INTRAVENOUS INFUSION.
Generic name: Paclitaxel
Brand name: Onceace
Class: Antineoplastic (Chemotherapy Drug)
Pack size: 1 vial(50ml)
Form: Infusion
Strength: 300mg
Amount: ₦‎48,000

Description: Zaxol-300 contains Paclitaxel, a chemotherapeutic agent used in cancer treatment. It is primarily administered through intravenous infusion. This medication is available in a 300 mg/50 ml strength and must be diluted before administration. It is used under the supervision of a qualified oncologist to treat various types of cancers, including breast, ovarian, and lung cancer.

Key features:
• Concentration: 300mg/50ml
• Administration Route: Intravenous infusion
• Packaging: Single-use vial

Side Effects:
Common side effects include:
• Nausea and vomiting
• Hair loss
• Bone marrow suppression (low blood cell counts)
• Neuropathy (nerve damage leading to tingling or numbness)
• Fatigue
• diarrhoea
• Increased risk of infections

Caution:
• Only to be used under the guidance of a trained oncologist.
• Monitor for allergic reactions during infusion.
• Contraindicated in patients with hypersensitivity to Paclitaxel.
• Use with caution in patients with liver impairment.
• Regular blood tests are required to monitor blood cell levels.
• Pregnancy Category D: May cause harm to a foetus.
• Avoid use in breastfeeding mothers.

Weight 87 g

Reviews

There are no reviews yet.

Be the first to review “ZAXOL-300 (Paclitaxel Injection 300mg/50ml)”

Your email address will not be published. Required fields are marked *

Back To Top